The PI3K pathway has been described in several studies to regulate glucose metabolism in cancer [51, 52], thus our findings on inhibitory effects on CXCR4 expression and EGFR activation/expression could be involved in the reduction of glycolytic flux by the inhibition of PI3K/AKT axis. Here, AKT1 is linked to cancer.